

Chapter 145

Cutaneous Lymphoma

Marc Beyer & Wolfram Sterry

REFERENCES

1. Willemze R et al: WHO-EORTC classification for cutaneous lymphomas. *Blood* **105**:3768, 2005
2. Swerdlow SH et al: *WHO classification of tumours of hematopoietic and lymphoid tissues*, 4th edition. Lyon IARC Press 2008
3. Assaf C et al: Classification of primary cutaneous lymphomas. *Front Radiat Ther Oncol* **39**:25, 2006
4. Kim EJ et al: Immunopathogenesis and therapy of cutaneous T cell lymphoma. *J Clin Invest* **115**:798, 2005
5. Weinstock MA, Gardstein B: Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. *Am J Public Health* **89**:1240, 1999
6. Tan RS et al: Mycosis fungoides—a disease of antigen persistence. *Br J Dermatol* **91**:607, 1974
7. Jackow CM et al: HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. *J Invest Dermatol* **107**:373, 1996
8. Hodak E et al: Mycosis fungoides: HLA class II associations among Ashkenazi and non-Ashkenazi Jewish patients. *Br J Dermatol* **145**:974, 2001
9. Pancake BA, Zucker-Franklin D, Coutavas EE: The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients. *J Clin Invest* **95**:547, 1995
10. Zendri E et al: The HTLV tax-like sequences in cutaneous T-cell lymphoma patients. *J Invest Dermatol* **128**:489, 2008
11. Courgnaud V et al: Absence of HTLV-related sequences in skin lesions and peripheral blood of cutaneous T-cell lymphomas. *J Invest Dermatol* **129**:2520, 2009
12. Pawlaczyk M et al: No evidence of HTLV-I infection in patients with mycosis fungoides and Sezary syndrome. *Neoplasma* **52**:52, 2005
13. Bazarbachi A et al: Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: An international study. *Br J Haematol* **98**:927, 1997
14. De Francesco MA et al: Polymorphism analysis of Epstein-Barr virus isolates of lymphoblastoid cell lines from patients with mycosis fungoides. *J Med Microbiol* **53**:381, 2004
15. Novelli M et al: Epstein-Barr virus in cutaneous T-cell lymphomas: Evaluation of the viral presence and significance in skin and peripheral blood. *J Invest Dermatol* **129**:1556, 2009
16. Quintanilla-Martinez L, Kimura H, Jaffe ES: EBV-positive T-cell lymphoproliferative disorders of childhood. In: *WHO classification of tumours of haematopoietic and Lymphoid Tissues*, edited by SH Swerdlow, E Campo, NL Harris et al. Lyon, IARC Press, 2008 p. 278
17. Vonderheid EC, Bigler RD, Hou JS: On the possible relationship between staphylococcal superantigens and increased Vbeta5.1 usage in cutaneous T-cell lymphoma. *Br J Dermatol* **152**:825, 2005
18. Jackow CM et al: Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive *Staphylococcus aureus*, and oligoclonal T-cell receptor V beta gene expansion. *Blood* **89**:32, 1997
19. Tokura Y et al: Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: A potential role for bacterial superantigens. *Br J Dermatol* **133**:6, 1995
20. Talpur R, Bassett R, Duvic M: Prevalence and treatment of *Staphylococcus aureus* colonization in patients with mycosis fungoides and Sézary syndrome. *Br J Dermatol* **159**:105, 2008
21. Whittemore AS et al: Mycosis fungoides in relation to environmental exposures and immune response: A case-control study. *J Natl Cancer Inst* **81**:1560, 1989
22. Morales-Suárez-Varela MM et al: Occupational risk factors for mycosis fungoides: A European multicenter case-control study. *J Occup Environ Med* **46**:205, 2004
23. Girardi M, Heald PW, Wilson LD: The pathogenesis of mycosis fungoides. *N Engl J Med* **350**:1978, 2004
24. Dummer R et al: Pathogenesis of cutaneous lymphomas. *Semin Cutan Med Surg* **19**:78, 2000

25. Kieffer JD et al: Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: Cutaneous lymphocyte antigen. *Biochem Biophys Res Commun* **285**:577, 2001
26. Picker LJ et al: Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells. *J Immunol* **150**:1122, 1993
27. Magro CM, Dysen ME: Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates. *J Cutan Pathol* **35**:1040, 2008
28. Kakinuma T et al: Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: Serum TARC levels reflect the disease activity of mycosis fungoides. *J. Am. Acad. Dermatol* **48**:23, 2003
29. Lu D et al: Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. *J Cutan Pathol* **29**:465, 2002
30. Lu D et al: The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. *Am J Clin Pathol* **115**:413, 2001
31. Surh CD, Sprent J: Homeostasis of naive and memory T cells. *Immunity* **29**:848, 2008
32. Qin JZ et al: Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myc genes in cutaneous T-cell lymphoma cells. *Blood* **98**:2778, 2001
33. Yamanaka K et al: Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. *Blood* **107**:2440, 2006
34. Karenko L, Hahtola S, Ranki A: Molecular cytogenetics in the study of cutaneous T-cell lymphomas (CTCL). *Cytogenet Genome Res* **118**:353, 2007
35. van Doorn R et al: Oncogenomic analysis of mycosis fungoides reveals major differences with Sézary syndrome. *Blood* **113**:127, 2009
36. Adhikary S, Eilers M: Transcriptional regulation and transformation by Myc proteins. *Nat Rev Mol Cell Biol* **6**:635, 2005
37. Vermeer MH et al: Novel and highly recurrent chromosomal alterations in Sézary syndrome. *Cancer Res* **68**:2689, 2008
38. Caprini E et al: Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. *Cancer Res* **69**:8438, 2009
39. Reichmann E: The biological role of the Fas/FasL system during tumor formation and progression. *Semin Cancer Biol* **12**:309, 2002
40. Zoi-Toli O et al: Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): Association between lack of Fas expression and aggressive types of CTCL. *Br J Dermatol* **143**:313, 2000
41. Braun FK et al: Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. *J Invest Dermatol* **127**:2425, 2007
42. Hanahan D, Weinberg R: The hallmarks of cancer. *Cell* **100**:57, 2000
43. Asadullah K et al: Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. *J Invest Dermatol* **107**:833, 1996
44. Heald P et al: Treatment of erythrodermic cutaneous T cell lymphoma with extracorporeal photochemotherapy. *J Am Acad Dermatol* **27**:427, 1992
45. Hoppe RT et al: CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. *J Am Acad Dermatol* **32**:448, 1995
46. Berger CL et al: Cutaneous T-cell lymphoma: Malignant proliferation of T-regulatory cells. *Blood* **105**:1640, 2005
47. Heid JB et al: FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome. *J Invest Dermatol* **129**:2875, 2009
48. Kempf W et al: Granulomatous mycosis fungoides and granulomatous slack skin: A multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). *Arch Dermatol* **144**:1609, 2008
49. Vonderheid EC et al: Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. *J Am Acad Dermatol* **46**:95, 2002
50. Kim YH et al: Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. *Arch Dermatol* **139**:857, 2003
51. Burg G et al: WHO/EORTC classification of cutaneous lymphomas. Histological and molecular aspects. *J Cutan Pathol* **32**:647, 2005
52. Bekkenk MW et al: Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: A report from the Dutch Cutaneous Lymphoma

- Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. *Blood* 95:3653, 2000
53. Kadin ME, Carpenter C: Systemic and primary cutaneous anaplastic large cell lymphomas. *Semin Hematol* 40:244, 2003
 54. Duvic M et al: A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. *Clin Cancer Res* 15:6217, 2009
 55. Willemze R et al: Subcutaneous panniculitis-like T-cell lymphoma: Definition, classification, and prognostic factors: An EORTC Cutaneous Lymphoma Group Study of 83 cases. *Blood* 111:838, 2008
 56. Assaf C et al: CD56-positive haematological neoplasms of the skin: A multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. *J Clin Pathol* 60:981, 2007
 57. Berti E et al: Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. *Am J Pathol* 155:483, 1999
 58. Beltraminelli H et al: Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: A cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. *Am J Dermatopathol* 31:317, 2009
 59. Sterry W, Siebel A, Mielke V: HTLV1-negative pleomorphic T cell lymphoma of the skin. The clinicopathologic correlations and natural history of 15 patients. *Br J Dermatol* 126:456, 1992
 60. Olsen E et al: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood* 110:1713, 2007
 61. Kim YH et al: TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood* 110:479, 2007
 62. Trautinger F et al: EORTC consensus recommendations for the treatment of mycosis fungoides/ Sézary syndrome. *Eur J Cancer* 42:1014, 2006
 63. Vonderheid EC et al: Long-term efficacy, curative potential and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. *J Am Acad Dermatol* 20:416, 1989
 64. Breneman D et al: Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. *Arch Dermatol* 138:325, 2002
 65. Zhang C, Duvic M: Retinoids: Therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. *Dermatol Ther* 16:322, 2003
 66. Herrmann JJ et al: Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow up. *J Am Acad Dermatol* 33:234, 1995
 67. Rosenbaum MM et al: Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques. Long-term follow-up in forty-three patients. *J Am Acad Dermatol* 13:613, 1985
 68. Duvic M et al: Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. *Arch Dermatol* 137:581, 2001
 69. Assaf C et al: Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: An expert opinion. *Br J Dermatol* 155:261, 2006
 70. Wilson LD et al: Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. *Int J Radiat Oncol Biol Phys* 15:987, 1995
 71. Stadler R et al: Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. *Blood* 92:3578, 1998
 72. Ross C et al: Interferon treatment of cutaneous T cell lymphoma. *Eur J Haematol* 51:63, 1993
 73. Olsen E et al: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. *J Clin Oncol* 19:376, 2001
 74. Lundin J et al: Phase II Study of Alemtuzumab (Campath-1H) in patients with advanced Mycosis fungoides/Sezary syndrome. *Blood* 101:4267, 2003
 75. Bernengo MG et al: Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: Clinical and immunologic findings in 14 patients. *Haematologica* 92:784, 2007

76. Duvic M et al: Phase 2 trial of oral SAHA (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). *Blood* **109**:31, 2007
77. Dijkman R et al: Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. *Blood* **107**:4926, 2006
78. Deutsch AJ et al: Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation. *J Invest Dermatol* **129**:476, 2009
79. Liu M, Schatz DG: Balancing AID and DNA repair during somatic hypermutation. *Trends Immunol* **30**:173, 2009
80. Hoefnagel JJ et al: Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. *Blood* **105**:3671, 2005
81. van Galen JC et al: Profiling of apoptosis genes identifies distinct types of primary cutaneous large B cell lymphoma. *J Pathol* **215**:340, 2008
82. van Maldegem F et al: The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. *Blood* **112**:3355, 2008
83. Kutzner H et al: CD123-positive plasmacytoid dendritic cells in primary cutaneous marginal zone B-cell lymphoma: Diagnostic and pathogenetic implications. *Am J Surg Pathol* **33**:1307, 2009
84. Senff NJ et al: Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: Comparison with previous classifications and identification of prognostic markers. *J Clin Oncol* **25**:1581, 2007
85. Kerl H, Kodama K, Cerroni L: Diagnostic principles and new developments in primary cutaneous B-cell lymphomas. *J Dermatol Sci* **34**(3):167, 2004
86. Hoefnagel JJ et al: Primary cutaneous marginal zone B-cell lymphoma: Clinical and therapeutic features in 50 cases. *Arch Dermatol* **141**(9):1139, 2005
87. Valencak J et al: Rituximab monotherapy for primary cutaneous B-cell lymphoma: Response and follow-up in 16 patients. *Ann Oncol* **20**:326, 2009
88. Senff NJ et al: Fine-mapping chromosomal loss at 9p21: Correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. *J Invest Dermatol* **129**:1149, 2009
89. Senff NJ et al: European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. *Blood* **112**:1600, 2008
90. Senff NJ, Kluijn-Nelemans HC, Willemze R: Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. *Br J Haematol* **142**:52, 2008
91. Senff NJ, Willemze R: The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: Results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. *Br J Dermatol* **157**:1205, 2007